Antibody-drug Conjugates & Bioconjugates
|Column 1||Column 2|
|PATIENT||Reporting on 22 heavily pre-treated patients with relapsed/refractory B-cell lymphoma in dose escalation phase. Dose expansion phase will proceed at 7.5 mg/kg.|
Two dose limited-toxicities (transient elevation of liver enzymes at 4.2 and 10mg/kg); no DLTs observed at 7.5mg/kg. One other patient discontinued treatment due to grade 3 ocular adverse event (dry eye, blurred vision).
Other adverse events were those commonly associated with ADCs, including neutropenia and thrombocytopenia. These were infrequent and resolved without intervention.
Peripheral neuropathy, a common side-effect observed with maytansine/MMAE conjugates and one that is commonly associated with treatment discontinuation, was infrequent and only observed in patients with prior history of neuropathy.
|EFFICACY||6 complete responses and 2 partial responses observed in patients with both indolent and aggressive disease (including DLBCL and mantle cell lymphoma).|
|PHARMACOKINETICS||TRPH-222 has high stability in humans; no evidence of released payload in circulation, even at 10 mg/kg dose.|
Molecular Cancer Therapeutics: CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
OncoImmunology: Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells